StockLens

Aurobindo Pharma Limited (AUROPHARMA) share price and analysis

AUROPHARMA last traded at ₹1,794.10 (+0.01%) on the NSE. Market cap ₹1,03,229 Cr (Large cap), Pharma & Healthcare sector.

Overall rating: 8.1/10 (Excellent)

Long-term view: Strong long-term candidate. Business quality and valuation clearly outweigh the weaknesses. Trade bias (next few weeks): Strong long. Trend and momentum are clearly pointing up.

Strengths of AUROPHARMA

Key numbers

NumberValueAssessmentNormal range
P/E (TTM)26.0Cheaper than peers37.0–49.3 (sector median 41.1)
Forward P/E18.7Profits expected to growbelow today's P/E (26.0) and near 41
Price / book2.62Normal2–6
EPS (TTM)₹69.05Profitableabove ₹0
Return on equity10.7%Average15%+ (below 10% is weak)
Debt / equity0.22Low debtbelow 1.0 (under 0.5 is great)
Net margin10.8%Healthy10%+ (below 5% is thin)
Operating margin15.5%Average20%+ strong, below 10% thin
Revenue growth+23.9%Growing well10%+ a year (below 3% is weak)
Profit growth+33.9%Growing well10%+ a year (falling is weak)
Dividend yield0.78%Small payout1.5%+ (none is fine for growth firms)
Current ratio1.73Comfortable1.5+ (below 1 is tight)
52W high₹1,859.904% below · near the highprice in the top 40% of its 52-week range
52W low₹1,106.00Price is 62% above it
50-DMA₹1,693.33Price 6.0% aboveprice above it = short-term uptrend
200-DMA₹1,490.95Price 20.3% aboveprice above it = long-term uptrend
1Y return+59.6%Beat the Nifty 50Nifty 50 did −0.4%
Beta0.02Steadier than the market0.8–1.3 (1 = moves with market)
Promoter / insider54.8%Owners have a big stake50%+ shows owner commitment
Institutions29.7%Moderate interest30%+ is strong
Analyst target₹1,870.674.3% upside · 27 analysts8%+ upside

Questions about AUROPHARMA

What is the share price of Aurobindo Pharma Limited (AUROPHARMA) today?

AUROPHARMA last traded at ₹1,794.10 (+0.01% on the day) on the NSE. Its 52-week range is ₹1,106.00 to ₹1,859.90. Prices are delayed and come from Yahoo Finance.

Is AUROPHARMA a good stock for the long term?

StockLens rates AUROPHARMA 8.1 out of 10 (Excellent) overall. Its long-term verdict is "Strong long-term candidate": Business quality and valuation clearly outweigh the weaknesses. Strengths: cheap vs peers, uptrend, revenue growth.

Is AUROPHARMA share overvalued?

AUROPHARMA trades at a P/E of 26.0 against a Pharma & Healthcare median of 41.1, which StockLens rates as "Cheaper than peers". Its price-to-book ratio is 2.62.

Is AUROPHARMA good for short-term trading?

The trade bias for the next few weeks is "Strong long": Trend and momentum are clearly pointing up. The price is 20.3% above its 200-day average and 14-day RSI is 61.

Which stocks are similar to AUROPHARMA?

Similar Pharma & Healthcare stocks of comparable size include Max Healthcare, Cipla, Dr. Reddy's Laboratories, Lupin, Zydus Lifesciences. You can compare up to 4 of them side by side on StockLens.

About Aurobindo Pharma Limited

Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally. The company manufactures a range of finished formulation products in various forms, such as oral solids, liquids, injectables for generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients for CNS, anti-retroviral, cardiovascular, antibiotics, gastroenterology, anti-diabetics, and anti-allergic therapeutic areas. It also provides ointments, creams, gels, powders, transdermal, and lotions; antiretroviral drugs for PLHIV & CLHIV; and injectable products, including Penems, Penicillin, Cephalosporin, ophthalmic, inhalation, oncology, and hormone products. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

Stocks similar to AUROPHARMA

Compare AUROPHARMA with MAXHEALTH, CIPLA, DRREDDY

Educational information, not investment advice. Data from Yahoo Finance and NSE Indices; prices may be delayed.